Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota

Atherosclerosis

Volumn 241, Issue 2, 2015, Pages 387-399

  Org, Elin ^a   Mehrabian, Margarete ^a   Lusis, Aldons J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Germ free mice; Host gut microbiota interactions; Mucosal immune system; Polyphenolic metabolites; Systems biology approach; Trimethylamine N oxide

Indexed keywords

APOLIPOPROTEIN E; BACTERIAL ENZYME; LIPID; METHYLAMINE; POLYPHENOL DERIVATIVE; SHORT CHAIN FATTY ACID; BIOLOGICAL MARKER;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL METABOLISM; ENERGY METABOLISM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENETIC VARIABILITY; HELICOBACTER PYLORI; HEPATITIS A VIRUS; HEREDITY; HUMAN; HYDROLYSIS; IMMUNE SYSTEM; INFECTION; INTESTINE FLORA; LIPID BLOOD LEVEL; LIPID DIET; METAGENOMICS; MICROBIAL COMMUNITY; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOGENESIS; PORPHYROMONAS GINGIVALIS; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; ADVERSE EFFECTS; ANIMAL; BACTERIUM; BLOOD; CLASSIFICATION; DIET; DISEASE MODEL; ENVIRONMENT; GASTROINTESTINAL TRACT; GENETIC PREDISPOSITION; GENETICS; GENOTYPE ENVIRONMENT INTERACTION; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; RISK FACTOR; SYSTEMS BIOLOGY;

ANIMALS; ATHEROSCLEROSIS; BACTERIA; BIOMARKERS; DIET; DISEASE MODELS, ANIMAL; ENVIRONMENT; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HOST-PATHOGEN INTERACTIONS; HUMANS; RISK FACTORS; SYSTEMS BIOLOGY;

EID: 84936805972     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.05.035     Document Type: Review

References (138)

1. Holmes E., et al. Therapeutic modulation of microbiota-host metabolic interactions. Sci. Transl. Med. 2012, 4(137):137rv6.
2. Hooper L.V., Littman D.R., Macpherson A.J. Interactions between the microbiota and the immune system. Science 2012, 336(6086):1268-1273.
3. Nicholson J.K., et al. Host-gut microbiota metabolic interactions. Science 2012, 336(6086):1262-1267.
4. Hooper L.V., Macpherson A.J. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 2010, 10(3):159-169.
5. Maynard C.L., et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012, 489(7415):231-241.
6. Ravel J., et al. Vaginal microbiome of reproductive-age women. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(Suppl. 1):4680-4687.
7. Yatsunenko T., et al. Human gut microbiome viewed across age and geography. Nature 2012, 486(7402):222-227.
8. Carmody R.N., et al. Diet dominates host genotype in shaping the murine gut microbiota. Cell. Host Microbe 2015, 17(1):72-84.
9. Bolnick D.I., et al. Individual diet has sex-dependent effects on vertebrate gut microbiota. Nat. Commun. 2014, 5:4500.
10. Benson A.K., et al. Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(44):18933-18938.
11. Parks B.W., et al. Genetic control of obesity and gut microbiota composition in response to high-fat, high-sucrose diet in mice. Cell. Metab. 2013, 17(1):141-152.
12. Goodrich J.K., et al. Human genetics shape the gut microbiome. Cell 2014, 159(4):789-799.
13. Spor A., Koren O., Ley R. Unravelling the effects of the environment and host genotype on the gut microbiome. Nat. Rev. Microbiol. 2011, 9(4):279-290.
14. Turnbaugh P.J., et al. A core gut microbiome in obese and lean twins. Nature 2009, 457(7228):480-484.
15. Holmes E., et al. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell. Metab. 2012, 16(5):559-564.
16. Caporaso J.G., et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 2010, 7(5):335-336.
17. Schloss P.D., et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 2009, 75(23):7537-7541.
18. Huse S.M., et al. VAMPS: a website for visualization and analysis of microbial population structures. BMC Bioinforma. 2014, 15:41.
19. Nguyen T.L., et al. How informative is the mouse for human gut microbiota research?. Dis. Model Mech. 2015, 8(1):1-16.
20. Kolars J.C., et al. Yogurt-an autodigesting source of lactose. N. Engl. J. Med. 1984, 310(1):1-3.
21. Hooper L.V., Midtvedt T., Gordon J.I. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev. Nutr. 2002, 22:283-307.
22. Delzenne N.M., Cani P.D. Interaction between obesity and the gut microbiota: relevance in nutrition. Annu Rev. Nutr. 2011, 31:15-31.
23. Everard A., et al. Microbiome of prebiotic-treated mice reveals novel targets involved in host response during obesity. ISME J. 2014, 8(10):2116-2130.
24. Wright S.D., et al. Infectious agents are not necessary for murine atherogenesis. J. Exp. Med. 2000, 191(8):1437-1442.
25. Stepankova R., et al. Absence of microbiota (germ-free conditions) accelerates the atherosclerosis in ApoE-deficient mice fed standard low cholesterol diet. J. Atheroscler. Thromb. 2010, 17(8):796-804.
26. Koeth R.A., et al. Gamma-butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell. Metab. 2014, 20(5):799-812.
27. Koeth R.A., et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19(5):576-585.
28. Hanage W.P. Microbiology: microbiome science needs a healthy dose of scepticism. Nature 2014, 512(7514):247-248.
29. Gilbert A., Lion G. Arterites infectueuses expérimentales. Comptes Rendus Hebd. des Seances Mem. de la Soc. de Biol. 1889, 41:583-584.
30. Mattila K.J., et al. Association between dental health and acute myocardial infarction. BMJ 1989, 298(6676):779-781.
31. Rosenfeld M.E., Campbell L.A. Pathogens and atherosclerosis: update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb. Haemost. 2011, 106(5):858-867.
32. Saikku P., et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann. Intern Med. 1992, 116(4):273-278.
33. Stassen F.R., Vainas T., Bruggeman C.A. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol. Rep. 2008, 60(1):85-92.
34. Godzik K.L., et al. In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae. J. Clin. Microbiol. 1995, 33(9):2411-2414.
35. Blessing E., et al. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 2001, 158(1):13-17.
36. Coombes B.K., Mahony J.B. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Infect. Immun. 1999, 67(6):2909-2915.
37. Hu H., Pierce G.N., Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J. Clin. Invest 1999, 103(5):747-753.
38. Kalayoglu M.V., Byrne G.I. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J. Infect. Dis. 1998, 177(3):725-729.
39. Muhlestein J.B., et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998, 97(7):633-636.
40. Rosenfeld M.E. Inflammation and atherosclerosis: direct versus indirect mechanisms. Curr. Opin. Pharmacol. 2013, 13(2):154-160.
41. Johnston S.C., et al. Chlamydia pneumoniae burden in carotid arteries is associated with upregulation of plaque interleukin-6 and elevated C-reactive protein in serum. Arterioscler. Thromb. Vasc. Biol. 2005, 25(12):2648-2653.
42. Kol A., et al. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 1998, 98(4):300-307.
43. Hogdahl M., Soderlund G., Kihlstrom E. Expression of chemokines and adhesion molecules in human coronary artery endothelial cells infected with Chlamydia (Chlamydophila) pneumoniae. APMIS 2008, 116(12):1082-1088.
44. Kol A., et al. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest 1999, 103(4):571-577.
45. Duewell P., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464(7293):1357-1361.
46. Rajamaki K., et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010, 5(7):e11765.
47. Robbins G.R., Wen H., Ting J.P. Inflammasomes and metabolic disorders: old genes in modern diseases. Mol. Cell. 2014, 54(2):297-308.
48. Ridker P.M., et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000, 342(12):836-843.
49. Campbell L.A., et al. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Microb. Infect. 2010, 12(8-9):598-606.
50. Campbell L.A., Rosenfeld M.E. Persistent C. pneumoniae infection in atherosclerotic lesions: rethinking the clinical trials. Front. Cell. Infect. Microbiol. 2014, 4:34.
51. Koren O., et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 2010, 108(Suppl. 1):4592-4598.
52. Calandrini C.A., et al. Microbial composition of atherosclerotic plaques. Oral Dis. 2012, 20(3):e128-e134.
53. Wostmann B.S., et al. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab. Anim. Sci. 1983, 33(1):46-50.
54. Turnbaugh P.J., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444(7122):1027-1031.
55. Ley R.E., et al. Obesity alters gut microbial ecology. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(31):11070-11075.
56. Ridaura V.K., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341(6150):1241214.
57. Natarajan N., Pluznick J.L. From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology. Am. J. Physiol. Cell. Physiol. 2014, 307(11):C979-C985.
58. Iwanaga T., et al. Cellular expression of monocarboxylate transporters (MCT) in the digestive tract of the mouse, rat, and humans, with special reference to slc5a8. Biomed. Res. 2006, 27(5):243-254.
59. Bjursell M., et al. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2010, 300(1):E211-E220.
60. Ge H., et al. Activation of G protein-coupled receptor 43 in adipocytes leads to inhibition of lipolysis and suppression of plasma free fatty acids. Endocrinology 2008, 149(9):4519-4526.
61. Pluznick J.L., et al. Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(11):4410-4415.
62. Jin C., Henao-Mejia J., Flavell R.A. Innate immune receptors: key regulators of metabolic disease progression. Cell. Metab. 2013, 17(6):873-882.
63. Ding Y., et al. Toll-like receptor 4 deficiency decreases atherosclerosis but does not protect against inflammation in obese low-density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2012, 32(7):1596-1604.
64. Jin T., et al. Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity 2012, 36(4):561-571.
65. Henao-Mejia J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482(7384):179-185.
66. Wlodarska M., et al. NLRP6 inflammasome orchestrates the colonic host-microbial interface by regulating goblet cell mucus secretion. Cell 2014, 156(5):1045-1059.
67. Bauernfeind F., et al. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J. Immunol. 2011, 187(2):613-617.
68. Latz E. The inflammasomes: mechanisms of activation and function. Curr. Opin. Immunol. 2010, 22(1):28-33.
69. Latz E., Xiao T.S., Stutz A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 2013, 13(6):397-411.
70. Trompette A., et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 2014, 20(2):159-166.
71. Gregor M.F., Hotamisligil G.S. Inflammatory mechanisms in obesity. Annu Rev. Immunol. 2011, 29:415-445.
72. Lusis A.J., Attie A.D., Reue K. Metabolic syndrome: from epidemiology to systems biology. Nat. Rev. Genet. 2008, 9(11):819-830.
73. David L.A., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505(7484):559-563.
74. Sandek A., Anker S.D., von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr. Drug Metab. 2009, 10(1):22-28.
75. Ghosh S.S., et al. Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice-role of intestinal permeability and macrophage activation. PLoS One 2014, 9(9):e108577.
76. Harte A.L., et al. High fat intake leads to acute postprandial exposure to circulating endotoxin in type 2 diabetic subjects. Diabetes Care 2012, 35(2):375-382.
77. Caricilli A.M., et al. Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. PLoS Biol. 2011, 9(12):e1001212.
78. Clarke S.F., et al. The gut microbiota and its relationship to diet and obesity: new insights. Gut. Microb. 2012, 3(3):186-202.
79. Islam K.B., et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011, 141(5):1773-1781.
80. Li T., Chiang J.Y. Bile acids as metabolic regulators. Curr. Opin. Gastroenterol. 2015, 31(2):159-165.
81. Velagapudi V.R., et al. The gut microbiota modulates host energy and lipid metabolism in mice. J. Lipid Res. 2009, 51(5):1101-1112.
82. Swann J.R., et al. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(Suppl. 1):4523-4530.
83. Wostmann B.S. Intestinal bile acids and cholesterol absorption in the germfree rat. J. Nutr. 1973, 103(7):982-990.
84. Sayin S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell. Metab. 2013, 17(2):225-235.
85. Li F., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 2013, 4:2384.
86. Joyce S.A., et al. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(20):7421-7426.
87. Zhang H., et al. Human gut microbiota in obesity and after gastric bypass. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(7):2365-2370.
88. Furet J.P., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010, 59(12):3049-3057.
89. Ryan K.K., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509(7499):183-188.
90. Wang D., et al. Gut microbiota metabolism of anthocyanin promotes reverse cholesterol transport in mice via repressing miRNA-10b. Circ. Res. 2012, 111(8):967-981.
91. Wang Z., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472(7341):57-63.
92. Tang W.H., Hazen S.L. The contributory role of gut microbiota in cardiovascular disease. J. Clin. Invest 2014, 124(10):4204-4211.
93. Tang W.H., et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 2013, 368(17):1575-1584.
94. Shih D.M., et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 2014, 56(1):22-37.
95. Gao X., et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J. Biosci. Bioeng. 2014, 118(4):476-481.
96. Tang W.H., et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015, 116(3):448-455.
97. Ayesh R., et al. The fish odour syndrome: biochemical, familial, and clinical aspects. BMJ 1993, 307(6905):655-657.
98. D'Angelo R., et al. FMO3 allelic variants in Sicilian and Sardinian populations: trimethylaminuria and absence of fish-like body odor. Gene 2013, 515(2):410-415.
99. Suska A., et al. G protein-coupled receptor mediated trimethylamine sensing. Biosens. Bioelectron. 2009, 25(4):715-720.
100. Wallrabenstein I., et al. Human trace amine-associated receptor TAAR5 can be activated by trimethylamine. PLoS One 2013, 8(2):e54950.
101. Hartiala J., et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler. Thromb. Vasc. Biol. 2014, 34(6):1307-1313.
102. Bennett B.J., et al. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell. Metab. 2013, 17(1):49-60.
103. Gregory J.C., et al. Transmission of atherosclerosis susceptibility with gut microbial transplantation. J. Biol. Chem. 2014, 290(9):5647-5660.
104. Brown J.M., Hazen S.L. The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev. Med. 2015, 66:343-359.
105. Kuka J., et al. Suppression of intestinal microbiota-dependent production of pro-atherogenic trimethylamine N-oxide by shifting L-carnitine microbial degradation. Life Sci. 2014, 117(2):84-92.
106. Brugere J.F., et al. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut. Microb. 2014, 5(1):5-10.
107. David L.A., et al. Host lifestyle affects human microbiota on daily timescales. Genome Biol. 2014, 15(7):R89.
108. Duncan S.H., et al. Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl. Environ. Microbiol. 2007, 73(4):1073-1078.
109. Louis P., et al. Understanding the effects of diet on bacterial metabolism in the large intestine. J. Appl. Microbiol. 2007, 102(5):1197-1208.
110. Zhang C., et al. Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. ISME J. 2010, 4(2):232-241.
111. Hildebrandt M.A., et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology 2009, 137(5). 1716-24 e1-2.
112. Joller D., et al. Refined localization of the Escherichia coli F4ab/F4ac receptor locus on pig chromosome 13. Anim. Genet. 2009, 40(5):749-752.
113. McKnite A.M., et al. Murine gut microbiota is defined by host genetics and modulates variation of metabolic traits. PLoS One 2012, 7(6):e39191.
114. Meijerink E., et al. A DNA polymorphism influencing alpha(1,2)fucosyltransferase activity of the pig FUT1 enzyme determines susceptibility of small intestinal epithelium to Escherichia coli F18 adhesion. Immunogenetics 2000, 52(1-2):129-136.
115. Niu X., et al. Refined mapping of the Escherichia coli F4ab/F4ac receptor gene(s) on pig chromosome 13. Anim. Genet. 2011, 42(5):552-555.
116. Vijay-Kumar M., et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 2010, 328(5975):228-231.
117. Fritz J.V., et al. From meta-omics to causality: experimental models for human microbiome research. Microbiome 2013, 1(1):14.
118. O'Connor A., et al. Responsiveness of cardiometabolic-related microbiota to diet is influenced by host genetics. Mamm. Genome 2014, 25(11-12):583-599.
119. Donia M.S., et al. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell 2014, 158(6):1402-1414.
120. Kim H.J., et al. Human gut-on-a-chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab. Chip 2012, 12(12):2165-2174.
121. Civelek M., Lusis A.J. Systems genetics approaches to understand complex traits. Nat. Rev. Genet. 2014, 15(1):34-48.
122. Consortium, H.M.P. Structure, function and diversity of the healthy human microbiome. Nature 2013, 486(7402):207-214.
123. Qin J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464(7285):59-65.
124. Li H. Systems biology approaches to epidemiological studies of complex diseases. Wiley Interdiscip. Rev. Syst. Biol. Med. 2013, 5(6):677-686.
125. Mitchell S.C., Zhang A.Q., Smith R.L. Chemical and biological liberation of trimethylamine from foods. J. Food Compos Anal. 2002, 15:277-282.
126. Rohrmann S., et al. Meat consumption and mortality-results from the European Prospective Investigation into Cancer and Nutrition. BMC Med. 2013, 11:63.
127. Ussher J.R., Lopaschuk G.D., Arduini A. Gut microbiota metabolism of L-carnitine and cardiovascular risk. Atherosclerosis 2013, 231(2):456-461.
128. Knight R. Why microbiome treatments could pay off soon. Nature 2015, 518:55.
129. Sonnenburg J.L. Microbiome engineering: synthetic biology may lead to the creation of smart microbes that can detect and treat disease. Nature 2015, 518:510.
130. Njoroge J., Sperandio V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol. Med. 2009, 1(4):201-210.
131. Citorik R.J., Mimee M., Lu T.K. Sequence-specific antimicrobials using efficiently delivered RNA-guided nucleases. Nat. Biotechnol. 2014, 32(11):1141-1145.
132. Cox L.M., Blaser M.J. Antibiotics in early life and obesity. Nat. Rev. Endocrinol. 2015, 11(3):182-190.
133. Hofmann A.F. Bile acid sequestrants improve glycemic control in type 2 diabetes: a proposed mechanism implicating glucagon-like peptide 1 release. Hepatology 2011, 53(5):1784.
134. Holst J.J. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007, 87(4):1409-1439.
135. Thomas C., et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell. Metab. 2009, 10(3):167-177.
136. Harach T., et al. TGR5 potentiates GLP-1 secretion in response to anionic exchange resins. Sci. Rep. 2012, 2:430.
137. Craciun S., Balskus E.P. Microbial conversion of choline to trimethylamine requires a glycyl radical enzyme. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(52):21307-21312.
138. Zhu Y., et al. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. U. S. A. 2014, 111(11):4268-4273.